Introduction
There has been a buzz in the pharma world about psychedelic compounds. Once on the fringes of research, these substances are now front and center in the quest for new psychiatric treatments. Companies are diving in, enticed by the promise these molecules hold, looking to harness the psychedelic properties of these molecules to treat psychiatric diseases with high unmet need. But, as with any burgeoning field, the road ahead is filled with both opportunities and obstacles.
